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Abstract
Over the last five years, large data sets on mortality in schizophrenia have been published which have established mortality as a measurable clinical
endpoint. Four issues need clarification: whether mortality rates are declining, what the causes of death are, the effects antipsychotic treatments have
on mortality and whether these data inform as to how mortality may be reduced in the future. A PubMed search was carried out to identify relevant
publications. The search strategy was conducted as a review focusing predominantly on data since 2006. A large number of retrospective epidemio-
logical and prospective studies have been published on mortality rates and causation in schizophrenia, predominantly from 2006–2009. Data suggest
that the mortality gap with the general population increased from the 1970s but may have peaked in the mid-1990s. The main causes of mortality are
suicide, cancer and cardiovascular disease, with evidence that cancer mortality rates are similar to cardiovascular mortality rates. Mortality causation is
dependent upon age of the cohort, length of follow up and type of study. Antipsychotic treatments reduce mortality when compared with no treatment
and atypical antipsychotics do not appear to increase cardiovascular mortality and morbidity compared with conventionals; further research is required
for any definitive conclusion.
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Introduction
In general medicine, mortality endpoints for treatments such
as thrombolysis in acute myocardial infarction and evaluation
of longer-term hypertension treatment have been common-
place since the mid-1980s (ISIS-2 Collaborative Group,
1988). By comparison, although the ﬁrst cited mention of
mortality in ‘lunacy’ dates from the 17th century (Graunt,
1662), psychiatry has been somewhat slow to accept this
clearly deﬁned endpoint. Over the previous 50 years, psychi-
atry has moved through many clinical endpoints, beginning
with the degree of noise reduction in long-stay hospital wards
through various rating scales, often too complex for clinical
usage, to more pragmatic endpoints including treatment dis-
continuation and hospital discharge and, most recently,
remission and recovery. Mortality has been regarded as a
potential clinical outcome measure in schizophrenia since
2005 (Drew, 2005) and represents a crucial variable with
which to compare the impact of various forms of treatment,
recently being described as the gold standard of clinical out-
come (Brown et al., 2010). Indeed, mortality can be viewed as
a good proxy for measurement of overall standard of care,
but it is additive and cannot replace other well-established
endpoints. For example, when evaluating cardiac-related out-
comes after treatment, it is a more robust endpoint than car-
diovascular morbidity (Kelly et al., 2010).
During the time period up to 2006, there have been a
number of excellent systematic reviews, meta-analyses and
clinical reviews detailing mortality rates and, to some
extent, the causation of mortality in schizophrenia compared
with the general population. The Brown meta-analysis
included 18 mortality studies of which only three derived
from Scandinavia with many studies coming from the USA
and the UK. However, many of these studies were relatively
small (Brown, 1997). The more recent advent of national
databases and registers primarily pioneered in Finland,
Sweden and Denmark has provided for the routine collection
of clinical information which has allowed mortality evalua-
tions in populations of signiﬁcant size. For example, the
Laursen et al. study included 3942 schizophrenia deaths
(Laursen et al., 2007).
In 2007, a systematic review (Saha et al., 2007) concluded
from data published up to that time that mortality rates in
schizophrenia were signiﬁcantly greater than in the general
population, median standardized mortality ratio (SMR) 2.58
(10–90% quantile, 1.18–5.76) and the mortality gap between
schizophrenia patients and the general population had contin-
ued to increase during the 1970s and 1980s. There seems little
doubt that these data are correct. Excess mortality in
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in various studies covering the time period from 1926 to 2000
ranges from SMR 1.51 to SMR 3.34 (Fors et al., 2007) with
length of follow up ranging from 4 to 40 years and cohort size
(not deaths) from 200 to 66,000. Furthermore, SMR for mor-
tality remains elevated until 80 years of age (Mortensen and
Juel, 1993). Some of these data have allowed mortality com-
parisons between schizophrenia and other forms of severe
mental illness (SMI). Laursen et al. reported a register-based
linkage study from Denmark comparing mortality rates and
causes among more than 250,000 psychiatric patients with
various types of SMI with over 20 years follow up (Laursen
et al., 2007). When schizophrenia was compared with unipolar
depressive disorder, bipolar aﬀective disorder and schizoaﬀec-
tive disorder, schizophrenia had a lower mortality from unnat-
ural causes of death but a higher mortality from natural causes
than the other forms of SMI.
The next question to address is what exactly do schizo-
phrenia patients die from? Data are fairly consistent, indicat-
ing that for almost all natural and unnatural causes of death,
the SMR is elevated (Saha et al., 2007; Laursen et al., 2009).
The commonly cited meta-analysis from Brown (1997) pro-
vided the statistic that the relative contributions to excess
mortality were suicide (28%), accidents (12%) and natural
causes (60%). This was an important data set that further
clariﬁed earlier ﬁndings from a 40-year follow up study of
male schizophrenia patients that concluded decreased survival
was caused by suicide, accidents and infectious diseases
(Tsuang et al., 1980). By 2001, there was an acceptance that
natural causes have a signiﬁcant role to play in elevating
schizophrenia mortality (Brown et al., 2000). The actual con-
tribution of each illness to mortality remains widely discussed
although until recently the primary focus was on cardiovas-
cular disease (CVD) rather than cancer, accidents or respira-
tory disorders.
Over the last 5 years, many more data have emerged that
were not available at the time of these earlier reviews and
2008–2009 in particular saw a plethora of mortality data
(Capasso et al., 2008; Dean and Thuras, 2009; Peuskens
et al., 2009; Tiihonen et al., 2009; Tran et al., 2009). The
purpose of this review is to evaluate mortality data that
have emerged since 2006 to determine whether any deﬁnitive
clinical answers can be derived and to propose clinical ques-
tions that may need to be addressed in future research. One
aspect of this is the realization that traditional, randomized
controlled trials alone are unlikely to provide deﬁnitive, long-
term mortality outcomes due to the need for large cohorts; in
contrast, country-speciﬁc databases allow for longer-term
follow up. There has been much debate over the use of clinical
data derived retrospectively from epidemiological databases
for illness such as diabetes in schizophrenia patients and the
appropriateness and quality of these databases needs to be
conﬁrmed (Bushe and Leonard, 2004, 2007; De Hert et al.,
2010). Thus, our review also considers the relevance of data-
bases when examining the mortality issue.
The main clinical questions to be addressed are as follows:
1. What is the current trend with respect to both mortality
rates in schizophrenia and the mortality gap with the gen-
eral population?
2. What are the current causes of mortality in schizophrenia
and is there evidence of any change in aetiology?
3. What eﬀects do antipsychotic treatments have on
mortality?
4. How well suited are databases to measuring mortality
rates?
5. Are there recommendations for future research?
Methods
A PubMed search was conducted using the Medical Subject
Heading (MeSH) terms ‘mortality’ and ‘schizophrenia’. The
search was conducted on data published in the English lan-
guage in the time period from January 2006 to January 2010.
The search was not deﬁned as a systematic review although
most of the Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) criteria were met. An initial search
found 101 references: 16 relevant publications, 5 letters in
reply, 10 case reports or series, 3 non-English language pub-
lications and 67 publications that were not considered rele-
vant. Reference lists of review papers were searched for
further publications and authors were contacted for further
data when relevant.
Results and clinical discussion
Current trends in mortality rates in schizophrenia and
the mortality gap with the general population
In 2007, a meta-analysis of mortality (Saha et al., 2007) found
that not only were mortality rates greater in schizophrenia
(median SMR 2.58) than in the general population, but that
there had been a linear increase in SMR over the previous
three decades leading to an increase in the mortality gap
(median SMRs for the 1970s, 1980s and 1990s were 1.84,
2.98 and 3.2, respectively). This incremental SMR was also
reported from Sweden during 1980–1995 (Osby et al., 2000),
but in this instance was attributed to deinstitutionalization.
The Saha meta-analysis was a seminal publication given that
37 studies were included detailing SMRs for diﬀerent causes
of deaths from 25 countries using data published in the period
1980–2006. Two previous meta-analyses using published data
from 1969–1996 reported all-cause SMRs of 1.51 and 1.57
(Brown, 1997; Harris and Barraclough, 1998). The Saha
et al. meta-analysis was also in agreement with other data
(Harris and Barraclough, 1998) that the increased risk of
mortality relates to men and women equally. This was postu-
lated to be due to a failure of schizophrenia patients to receive
the improving healthcare given to the general population and
this theory has been supported by many data sets including
the Western Australian CVD mortality and treatment data
from 1980–1998 (Lawrence et al., 2003; Kisely et al., 2009).
The hospital admission rates for CVD in schizophrenia
patients in the Australian study were 60% of those for the
general population despite mortality rate ratios (MRRs) for
males being 1.78. Furthermore, schizophrenia patients under-
went signiﬁcantly fewer revascularization procedures, around
only 30–35% of those received by the general population. In
the Saha analysis of studies published between 1980 and 2006,
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et al., 2007). Suicide was associated with the highest median
SMR (12.86) and cardiovascular mortality had a SMR of
1.79. A 2005 report from the National Association of State
Mental Health Program Directors found a mortality gap of
25 years between schizophrenia patients and the general pop-
ulation and concluded that 40% of the excess mortality was
related to suicide and other unnatural causes, with 60%
related to natural causes (Parks et al., 2006). Cardiovascular
mortality rose from 1976 to 1995, with the greatest increase
from 1991 to 1995. A small Swedish cohort (n¼255) followed
for 10 years up to 2000 found higher mortality rates in schizo-
phrenia patients (23%) than in the national population
(11.2%), relative risk (RR) 2.5 (p¼0.0001) (Fors et al., 2007).
There are, however, data that suggest that mortality rates
at worst peaked around 1995 or, at best, are in decline,
although data are not deﬁnitive. A confounder that is com-
plex to address is that in the USA even diﬀerent states have
been shown to have widely diﬀering SMRs in their respective
schizophrenia populations. For example, data from 1997
show SMRs varying from 2.0 to 4.9 (Colton and
Manderscheid, 2006) and it is reported that while in some
states, such as Texas, the SMR decreased over the period
1997 to 1999, no change was measured in other states
(Colton and Manderscheid, 2006). A meta-analysis found
the highest SMR from studies published in the 1980s (1.91)
rather than either the 1970s (1.52) or the 1990s (1.4) (Brown,
1997). Not all data however are in agreement. In a cohort
(n¼319) followed for a median of 23.5 years (1950–2005),
Capasso et al. (2008) in many ways replicated an earlier pub-
lished study (Tsuang et al., 1980) and reported an almost
identical survival curve over a 30-year period following diag-
nosis. Mortality was signiﬁcantly increased (p<0.001) com-
pared with a Caucasian Mid-Western USA population.
Ethnicity of comparative groups is often limited and may
represent an important confounder. Their conclusion was
that the mortality gap continued to increase versus the gen-
eral population. An 11-year follow up of the complete schizo-
phrenia population in Finland (n¼66,881) compared
mortality rates with the total Finnish population (5.2 million)
during 1996–2006 (Tiihonen et al., 2009). The mortality gap
versus the general population did not widen further and
showed a numerical decline from 25 years in 1996 to 22.5
years in 2006. Although the majority of mortality data
come from epidemiological-based studies, there are two
recent mortality studies with an open randomized design,
the ziprasidone observational study of cardiac outcomes
(ZODIAC) and the sertindole prospective cohort study
(SCOP) (ZODIAC, 2010; Peuskens et al., 2009). ZODIAC
randomized 18,154 patients to ziprasidone or olanzapine
with 1-year follow up between 2002 and 2007. The mortality
rate was identical in both cohorts (1.13%). SCOP randomized
9809 patients to sertindole or risperidone with 2-year follow
up over a similar time period to ZODIAC (2002–2007) and, at
the International Congress of Schizophrenia Research in
2009, a mortality rate of 0.8/100 person years was reported
(Peuskens et al., 2009). Hence, not only were both studies
randomized, recent and powered with a primary endpoint
of mortality, but both reported far lower mortality rates in
all cohorts than had been expected. SCOP was powered on an
anticipated mortality rate of 2/100 person years. The mortal-
ity rate per person-years of follow up in ZODIAC has not
been reported but can be estimated as between 1.2 and
1.7/100 person-years (based on either 18,000 or 12,000
person-years follow up). In contrast, the Dean and Thuras
mortality study undertaken over the time period 1991–2001
reports a mortality rate of 5.07/100 person-years (Dean and
Thuras, 2009). These data support a hypothesis that mortality
rates in schizophrenia are currently declining; it is unclear
whether the mortality gap with the general population is
also narrowing although evidence supports a plateau since
the mid-1990s. The Tran et al. prospective mortality study
suggests that in France the mortality gap may not be decreas-
ing with overall SMR for males and females 3.6 and 4.3,
respectively (Tran et al., 2009).
Current causes of mortality in schizophrenia
and evidence of any change in aetiology
The predominant causes of mortality in schizophrenia are
now well recognised to be cardiovascular, unnatural deaths
(including suicide), respiratory and cancer related. It is salient
to note, however, that it is only in the last 10 years that the
contribution of natural causes to this excess mortality has
been fully recognized. The Brown meta-analysis concluded
that there was a larger increase in SMR from suicide and
only a moderate increased SMR from natural causes
(Brown, 1997). Many studies and commentaries have, how-
ever, focused on CVD and not evaluated the role of other
natural causes particularly cancer and respiratory disease in
this elevated mortality (Barnett et al., 2007).
The actual contributions of CVD, cancer and suicide to
mortality rates are dependent on both the type of study,
length of follow up and cohort age. Studies that recruit
ﬁrst-episode patients will measure suicide mortality with
greater accuracy whereas studies that include populations
aged over 40–50 years are more likely to detect cancer
cases. In contrast, studies that follow patients outside these
age parameters may underestimate these causes of mortality.
These critical factors thus may be relevant when comparing
mortality causation across studies (Table 1). In addition, pro-
spective studies designed speciﬁcally to measure mortality will
provide greater accuracy of both mortality rates and causa-
tion (Tran et al., 2009; Peuskens et al., 2009). Comparison
across studies is further complicated by the fact that cause of
death is not reported uniformly with some studies combining
a number of causes. Furthermore, there are many other rele-
vant confounders which means that any form of adjustment is
impractical, including the availability of medications and
types of care provided during the study period.
Data from Australia (Lawrence et al., 2000) and Denmark
(Dalton et al., 2008) concur that mortality rates for most
major cancer types are elevated in schizophrenia when related
to their incidence. The debate over whether cancer incidence
is decreased in schizophrenia has been complex and is only
now being addressed systematically (Catts et al., 2008; Bushe
et al., 2009; Lichtermann et al., 2001). Cancer is probably the
wrong metric as it consists of many diﬀerent types with often
varying aetiologies and may be best explored individually.
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remains the single largest risk factor for a number of cancers.
Pragmatically, the clinically relevant question may be to
address the incidence of cancer without adjustment for pos-
tulated confounders. The two main cancers in schizophrenia
(lung and breast) have a higher incidence than the general
population (Bushe et al., 2009; Catts et al., 2008, Hippisley-
Cox et al., 2007). The study from Capasso et al. was the ﬁrst
to fully address the role of cancer in mortality elevation and
to discuss the implications (Capasso et al., 2008). Cancer is
also an illness of more elderly patients, with no evidence to
date that it is diagnosed at an earlier age in schizophrenia.
Many cohorts may not include substantial numbers of
patients over 50 years who are the cohort predominantly at
risk of incident cancer and subsequent mortality. One of the
ﬁndings from our previous work in breast cancer is that cer-
tain ‘quality factors’ need to be accounted for when analysing
cancer incidence rates, most critically, having a cohort where
there is signiﬁcant follow up after 50 years of age (Bushe
et al., 2009). In breast cancer, 80% of incident cases arise in
patients over 50 years (Bushe et al., 2009). Even in the
Capasso et al. cohort, the median age at study onset was 34
years with a median follow up of 23.5 years, yet the average
age of death of patients with cancer was 64 years. The Saha
et al. meta-analysis ﬁnds the median SMR for neoplastic
diseases elevated at 1.37 in contrast with CVD (1.79) and
suicide (12.86) (Saha et al., 2007). Neither age of the
cohort, nor person-years follow up is stated and this may
have implications for cancer mortality. One of the largest
mortality studies in schizophrenia following a cohort of
17,600 schizophrenia patients over a prolonged period that
extended to 28 years in some cases from 1973–2001 found
MRR for CVD 2.07 and 1.72, suicide 25.38 and 45.59 and
malignant neoplasms 1.24 and 1.32, for males and females,
respectively (Laursen et al., 2007). As with other data, the
cohort was relatively young with maximal cohort age of 48
years at the end of follow up and this may have led to lower
cancer mortality than expected. Recent data, both prospective
mortality studies and epidemiological cohort-based analyses,
have provided further information regarding the actual con-
tributions of these causes (Table 1). Data collected from
before 2000 in general ﬁnds CVD or circulatory disease to
be the most common cause of death. Fors et al. reported
46% deaths due to circulatory causes (CVD and cerebrovas-
cular accident [CVA]) during 1991–2000 follow up (Fors
et al., 2007).
A 55-year follow up study of 319 patients (median follow
up 23.5 years) published in 2008 (Capasso et al., 2008) found
cancer to be the second most common cause of death (19%),
with cardiovascular (CVD, arrhythmias and other cardiac
causes) the most common (29%). Suicide deaths were low
(3%), however, some suicides may have been misclassiﬁed
as ‘accidental’ deaths which accounted for 6% of the total
mortality. Diﬃculties in these analyses are emphasized by
the death certiﬁcate not being available in 9% of cases and
a further 9% of deaths being due to ‘unspeciﬁed causes’. The
strength of long-term follow up studies is that they allow for
the development of cancers from factors such as smoking
(Capasso et al., 2008; Lawrence et al., 2009). Recently, an
11-year prospective mortality study from France in 3470
schizophrenia patients reported a 14% mortality rate: suicide
4.2%, cancer 2.2%, CVD 2.0% and 1.4% attributed to ‘acci-
dental or non-suicide poisoning’. The mortality rate was
almost four-fold greater than in the general population
(SMR all cause death 3.6, 95% CI 3.3–3.9 for males and
SMR all cause death 4.3, 95% CI 3.7–5.1 for females).
Cancer was the second most frequent cause of mortality
(SMR 1.5, 95% CI 1.2–1.9) with 50% of cancer in males
Table 1. Causes of mortality in recent major schizophrenia studies
Mortensen
and Juel
(1993)
Brown
(1997)
Brown
et al.
(2000)
Fors
et al.
(2007)
Capasso
et al.
(2008)
Dean and
Thuras
(2009)
Tran
et al.
(2009)
a
Chong
et al.
(2009)
Characteristics
Cohort age (mean) n/a n/a 39 (male)
43 (female)
n/a 49 39 60
Study period 1970–1987 n/a 1981–1994 1991–2000 1950–2005 1991–2001 1993–2003 2000–2006
Follow up (years) 9 n/a 13 10 55 10 11 6
Cohort size 9156 66,161 370 255 319 1208 3434 608
Number of deaths 1100 10,260 79 59 140 205 476 72
Cause of death
b (%)
Cardiovascular 12 n/a 18 49
c 29 24 15 17
Cancer 7 n/a 18 19 19 21 16 17
Suicide 46 12 18 14 7 30 0
Cerebrovascular accident 3 n/a n/a n/a 8 n/a n/a
Accidental 11 n/a 4 5 10 n/a
Respiratory 17
Other natural causes n/a n/a 20 n/a 18 66
aAccidental deaths were defined as ‘accidental or non-suicide poisoning’.
bActual percentage of deaths based on total number of deaths.
cIncludes cerebrovascular accident.
n/a: Not available.
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rates would potentially be even greater if this category was
combined with the accidental or non-suicide poisoning
cohort, rising to 5.6%. A 10-year follow up study in the
USA in 1621 patients with a mean age of 49 years at ﬁrst
observation found 24% of deaths attributable to cardiovas-
cular causes compared with cancer (21%) and suicide (7%)
(Dean and Thuras, 2009).
Suicide. Suicide mortality rates may be best deﬁned using
ﬁrst episode studies and birth cohort studies as many suicides
happen in the early years of illness. The Northern Finland
1966 prospective population birth cohort followed 100 schizo-
phrenia patients from 16 years of age up until their 39th
birthday and found that 14% of the cohort had died. Half
of these deaths (n¼7) were the result of suicide, 2.9% females
and 9.2% males (Alara ¨ isa ¨ nen et al., 2009). In terms of com-
parison with other data sets, it is crucial that 71% of these
suicides occurred within the ﬁrst 3 years after onset of illness
and that suicide risk continues throughout the illness. This is
supported by Palmer et al.’s meta-analysis where suicide mor-
tality was signiﬁcantly greater in ﬁrst-episode cohorts than
those followed up later in their illness (5.6% and 1.8%,
respectively) (Palmer et al., 2005). Similar data come from a
ﬁrst-admitted 8-year follow up study in Denmark in 9156
schizophrenia patients where suicide accounted for 46% of
the 1100 deaths and accidents an additional 11%
(Mortensen and Juel, 1993). Suicide mortality is probably
higher than measured as around 25% of accidental and unde-
termined deaths are suicide (Allebeck et al., 1996). There is
little clarity as to any change in suicide rates as factors such as
deinstitutionalization of patients may be a confounder (Osby
et al., 2000).
Data from Wales showed that suicide rates were as much
as 20-fold higher in the 1990s than in the period 1875–1924,
although it is salient to note that the increase was from 0.5%
to 4.7% (Healy et al., 2006) and a review in 2005 found a
lifetime risk of 4.9% (Palmer et al., 2005), seemingly lower
than the 10–13% ﬁgure from Caldwell and Gottesman (1990).
The contribution of suicide to mortality thus varies widely
dependent on the age of the study cohort, length of follow up
and type of study and may be underestimated. The percentage
of all deaths attributed to suicide ranges from 0% to 46%
(Table 1).
Cardiovascular disease. There is little doubt that schizo-
phrenia patients have greater mortality from cardiovascular
disease than the general population. The UKGPRD study
found CVD mortality in schizophrenia to be elevated
almost four-fold (hazard ratio [HR] 3.61) in patients aged
18–49 years with a doubling of risk in the 50–75-year-old
cohort (HR 1.96) (Osborn et al., 2007). Mortensen and Juel
reported a SMR in men for CVD of 1.69 in a large ﬁrst-
admission cohort study of essentially young patients, with a
modal age at start of 25–29 years, and follow up of around
8 years. These data suggest that this enhanced CVD risk in
schizophrenia has an early onset (Mortensen and Juel, 1993)
and a recent Finnish ﬁrst episode study concluded that the
greatest SMR for CVD mortality was measured in the cohort
aged 20–24 years (Kiviniemi et al., 2010). However, the
number of deaths attributable to CVD is hugely variable
dependent on factors similar to those that aﬀect suicide mor-
tality rates and range from 12–46%.
Cancer. Cancer is recorded as the reason for death in 7–21%
of deaths (Table 1). The lowest ﬁgure of 7% comes from a
ﬁrst-admitted cohort followed for only 8 years and is thus
surprisingly high (Mortensen and Juel, 1993). There is a con-
sistency of cancer mortality rates in the other studies
(16–21%) which is not dissimilar to CVD mortality rates.
Only two studies with cohort ages at entry of 49 years and
60 years and follow up of 10 years and 6 years, respectively,
follow patients beyond the age at which cancer might be
expected to be diagnosed and relate to mortality (Chong
et al., 2009; Dean and Thuras, 2009).
Other natural causes. Speciﬁc causes of other natural
deaths are not recorded consistently across studies and
are seen to account for between 18% and 66% of all deaths
(Table 1) (Tran et al., 2009; Chong et al., 2009). Respiratory
causes and infections are common signiﬁcant contributors to
these ﬁndings, but, as for other causes, are partly dependent
on study type. This can be seen in an in-patient study in
elderly Asian patients where 66% of deaths were ascribed
to infections (Chong et al., 2009).
Overview of causes of death in schizophrenia
patients. Although numerically CVD is the most common
mortality cause in most studies, cancer is reported almost as
frequently. The type of study, cohort entry age and length of
follow up are all critical factors when reviewing mortality
data. Long-term follow up of ﬁrst episode patients prospec-
tively would be the optimum tool to answer this important
question. Studies that include younger cohorts and ﬁrst epi-
sode patients predominately measure suicide rates whereas
those that include older cohorts may be more accurate for
cancer mortality rates; studies that essentially miss these age
groups may under-report cancer and suicide deaths, and inad-
vertently report higher CVD mortality rates. These limita-
tions are relevant for future clinical research in mortality in
schizophrenia.
Antipsychotics and mortality
The premise has often been stated that second-generation
antipsychotics (SGAs) may increase cardiovascular risk as
many are associated with weight gain and worsening of met-
abolic parameters, often to a signiﬁcantly greater degree than
ﬁrst-generation antipsychotics (FGAs) (Lieberman et al.,
2005; Kahn et al., 2008). Clozapine, olanzapine and quetia-
pine are often cited as the antipsychotics with the most
adverse metabolic proﬁle (Hennekens et al., 2005). At present,
somewhat surprisingly, we could ﬁnd no evidence to support
this hypothesis of increased cardiovascular risk. In contrast,
many current data sets that compare FGAs and SGAs ﬁnd
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Osborn et al., 2007) or unchanged (Tiihonen et al., 2009)
cardiovascular morbidity and mortality with FGAs.
A 10-year follow up study in the USA in 1621 patients
with a mean age of 49 years at ﬁrst observation found
FGAs were associated with a doubling of mortality compared
with SGA (RR 2.00, 95% CI 1.13–3.53) and had numerically
greater association with cardiovascular mortality than SGA
(rates per 100,000/year; 519 and 1178, signiﬁcance not stated)
(Dean and Thuras, 2009). The UK GPRD study reported
signiﬁcantly lower CVD mortality in SMI patients taking
SGAs than FGAs (Osborn et al., 2007) and Enger et al.
reported a ﬁve-fold increased risk of myocardial infarction
in patients taking FGAs (Enger et al., 2004). During a 10-
year follow up, recent data have also shown that the risk of
CVD mortality does not diﬀer between risperidone and clo-
zapine despite known diﬀerences in their metabolic risk pro-
ﬁles (Kelly et al., 2010).
Where previously commentators have associated increased
CVD mortality rates to antipsychotics (De Hert et al., 2010;
Weinmann et al., 2009), it is salient to note that often these
studies evaluated essentially only FGA (Joukamaa et al.,
2006). The FIN 11 study concluded that mortality rates
were heterogeneous amongst antipsychotics and were able
to show dissonance in mortality rates between the individual
FGAs haloperidol and perphenazine (Tiihonen et al., 2009).
Overall mortality rates in the haloperidol cohort were signif-
icantly greater than the perphenazine cohort and some SGAs
(Tiihonen et al., 2009). This review cannot address the poten-
tial reasons for these ﬁndings but it may be salient to focus on
the recent ﬁnding that in a ﬁrst-episode cohort in Finland, the
greatest SMR for circulatory disease mortality was measured
in the cohort aged 20–24 years (Kiviniemi et al., 2010).
In 2010 there seems little doubt that antipsychotic treat-
ments reduce mortality with signiﬁcant mortality elevations
reported in the ﬁrst admitted Finnish cohort (2006) and
the complete Finnish cohort (2009), in patients who did not
take antipsychotic treatments, with worsening of outcomes
according to length of non-adherence to medications
(Tiihonen et al., 2006, 2009). Even in short-term clinical
trials there are similar ﬁndings (Khan et al., 2007; Issac and
Koch, 2010) where the US Food and Drug Administration
and European Medicines Agency have published mortality
rates for antipsychotics in comparison to placebo cohorts.
Schizophrenia patients in the placebo cohorts have elevated
mortality rates compared with antipsychotic cohorts. Poor
adherence to medication has been shown to be predictive of
suicide in both small case–control studies (Pompili et al., 2009)
and a large cohort study from Finland (Tiihonen et al., 2006).
Mortality rates in the large Finland study in ﬁrst admission
schizophrenia patients with a mean follow up of 3 years were
increased at least ﬁve-fold in the cohort not receiving any
medication (adjusted RR 37.4; 95% CI 5.1–276) for suicide
(Tiihonen et al., 2006) and by at least six-fold (adjusted RR
12.3: 95% CI 6.0–24.1) for overall mortality. In the 11-year
follow up study of all schizophrenia patients in Finland, long-
term exposure (7–11 years) to antipsychotic treatment was
associated with around a 20% lower mortality than no drug
use (Tiihonen et al., 2009) with an inverse relation between
length of treatment and mortality rate.
Polypharmacy has often been associated with increased
mortality (Joukamaa et al., 2006) though only with conven-
tionals. A recent Danish case–control study in over 27,000
schizophrenia patients over a 10-year follow up (1996–2005)
reported an unchanged mortality rate for the risk of natural
death when utilising antipsychotic polypharmacy with up to
three antipsychotics (conventionals were prescribed in 64% of
patients) (Baandrup et al., 2010). An association was, how-
ever, reported for increased mortality when using benzodiaz-
epines with a long elimination half-life (OR 1.78) that may
require further clariﬁcation. The current ﬁndings that SGA
have as a minimum similar associations with CVD mortality
with FGA do require further study and importantly may
require far longer follow up than currently reported.
The role of databases in measuring mortality rates
Population-based studies on mortality are possible in those
Nordic countries that have similar sets of administrative registers
of relevance to healthcare although their availability and com-
mencement dates vary somewhat between the countries. ‘Cause
of death’ registers are among the oldest registers in all of the
Nordic Countries, for example, the Finnish Causes of Death
Register maintained by Statistics Finland, provides date and
cause of death and also stores death certiﬁcates. The register
includes the personal identiﬁcation number of each deceased
person, sex, age, place of residence and principal, underlying
and contributory causes of death. The routine validation of
death certiﬁcates ensures that the accuracy of Nordic cause of
deathregistersisgoodbyinternationalstandards(Johanssonand
Westerling, 2000; Haukka et al., 2008; Lahti and Penttila ¨ , 2001).
Cause of death registers have been used in psychiatric
research for studying such topics as on mortality due to
various somatic disorders, and especially suicides (Heila ¨
et al., 2005).
In all Nordic countries it is, in principle, possible to link
information about psychiatric disorders such as schizophre-
nia to mortality data and to carry out large-scale, historical
cohort studies that allow research into the diﬀerences in mor-
tality (all-cause and cause-speciﬁc) between subpopulations
deﬁned by psychiatric disorders. However, databases may
not be operational in all Nordic countries and country-
speciﬁc conﬁdentiality issues may need to be addressed.
Thus, to interpret some of these data further, additional
data on prescribing and adherence will be required.
Conclusions
Mortality can now be regarded as an additional measurable
endpoint in schizophrenia that can supplement but not neces-
sarily replace other types of measured outcome. Data suggest
that mortality rates in schizophrenia have plateaued and may
even be in decline following a peak around 1995 although
further conﬁrmation is needed. The heterogeneity of many
of the cohorts combined with the relative short-term follow
up of the most recent data deriving from randomized con-
trolled trials make any deﬁnitive conclusions impossible. At
a minimum, however, there is no evidence that mortality rates
are further increasing although the degree to which this rela-
tive improvement is related to the advent of SGAs is
22 Journal of Psychopharmacology 24(11)speculative at this time. Evidence from three large studies is
supportive that mortality rates associated with the SGAs in
relation to CVD are lower than those of the FGAs (Enger
et al., 2004; Dean and Thuras, 2009; Osborn et al., 2007)
although this was not conﬁrmed in a recent 11-year mortality
follow up (Tiihonen et al., 2009). Any concerns over these
agents increasing cardiovascular mortality may have been
allayed in the short term, however it may be prudent to
await longer-term data before forming deﬁnitive views.
The utilization of SGAs increased in Finland from 13% to
64% during the period 1996 to 2006 with a similar pattern
worldwide. There remains a substantial mortality gap with
the general population however which needs to be addressed.
In contrast, each of the main causes of mortality can be fur-
ther addressed. Cardiovascular mortality rates could be
expected to decline with eﬀective health screening pro-
grammes and utilization of procedures and medications
such as statins, anti-hypertensives and hypoglycaemic drugs
which are currently grossly underused in schizophrenia
patients. Eﬀective medication regimes combined with
psycho-social treatments may reduce the suicide mortality.
Cancer mortality can be reduced by engagement of schizo-
phrenia patients in general population screening programmes.
There is increasing evidence that the two most common
cancers, breast and lung, have increased incidence rates in
schizophrenia, however, the impact of confounders such as
smoking and prolactin is unclear and adjusted cancer rates in
their absence are unknown. There is also a challenge to the
belief that suicide and CVD are the main causes of mortality
as cancer deaths may be of similar magnitude.
Future research into mortality needs to ascertain the success
of long-term treatments designed to reduce mortality rates and
to quantify important ﬁscal outcome measures that should
include quality-adjusted life-years (QALYS). The optimum
design for these studies may entail long-term, prospective
follow up of a large ﬁrst-episode cohort and, as a minimum,
researchers should be encouraged to standardize their method-
ology for reporting mortality causes to allow easier cross-study
comparisons. The interpretationofSMRsacrossvariedcohorts
is complex and any further research which reports age- and
stage-speciﬁc mortality from various causes may be instructive.
In particular, contemporaneous research utilizing doses of
FGAs lower than in the past and evaluating diﬀerent potency
FGAs needs to establish whether any mortality diﬀerential may
continue to be established with SGAs. Mortality is a robust
endpoint and it is to be expected that many of our remaining
questions will be addressed over the coming decades.
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